logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis

Achar J, Hewison CCH, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, Herboczek K, Rajabov AS, Hughes J, Ferlazzo G, Seddon JA, du Cros PAK
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.

Countries

Belarus South Africa Tajikistan Uzbekistan

Subject Area

antibiotic resistancetuberculosispediatricsantimicrobial resistanceadolescent health

Languages

English
DOI
10.3201/eid2310.170303
Published Date
01 Oct 2017
PubMed ID
28758889
Journal
Emerging Infectious Diseases
Volume | Issue | Pages
Volume 23, Issue 10, Pages 1711-1713
Issue Date
2017-10-01
Dimensions Badge